Recently, in an experimental study of an HF-induced mouse model, estrogen receptor-β agonists were used as immunomodulatory agents in order to antagonize estrogen receptor-α, whose sustained signaling is presumed to be implicated in the pathological activation of CD4+ cells during CHF. The gene discussed is CD4; the disease is hydrops fetalis.